Company: RNGE
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010872
Chunk: 21

Company: RANGE IMPACT, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
 all
remaining debt owed to him arising from the Company’s acquisition of Collins Building in August 2023. Any projects related to
Collins Building will be completed either by subcontractors or with equipment and resources of Range Environmental. The Company
recognized a net loss on the Collins Building sale of $3,043,799.
This sale did not constitute a discontinued operation as the Company has ongoing activities related to its acquisition of Collins
Building, and only certain assets were sold and debts
forgiven. As of March 31, 2025, any remaining active projects related to Collins Building will be completed by the previous owner or
his subcontractors  at the previous owner’s expense.

On September 30, 2024,
the Company sold all of its common stock of Graphium Biosciences to a newly-formed entity, Placer Biosciences, Inc. (“Placer”),
owned by two former officers of the Company, in exchange for a warrant to purchase 1,000
shares of Placer’s common stock (then representing 25%
of the outstanding shares of Placer) at $0.01
per share and cash proceeds of $100.
The warrant to purchase shares of Placer’s common stock expires on September 30, 2034.

Loss from Discontinued Operations

Discontinued
operations for the three months ended March 31, 2024 consists of results from Graphium Biosciences operations. The following table
provides details about the major classes of line items constituting “Loss from discontinued operations” presented on the
Company’s Consolidated Statements of Operations:

SCHEDULE
OF DISCONTINUING OPERATIONS INCOME STATEMENT

    March 31, 2024 

    Operating expenses: 

    Research and development 
    $131,640 
  
    Total operating expenses 
     131,640 

    Loss from discontinued operations 
    $(131,640)

5. EQUITY

Issuance of Common Stock

On January 21, 2025, the Company entered into a securities
purchase agreement for the issuance and sale of 3,333,333 shares of the Company’s common stock at a price of $0.15 per share. The aggregate proceeds to the Company were approximately
$500,000.

On February 6, 2025, the Company entered into a securities purchase agreement
for the issuance and sale of 555,556 shares of the Company’s common stock at a price of $0.18 per